Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J T Isaacs

Showing results (61-70 of 215) with videos related to

Pageof 22
Sort By:
Cancer Research|February 1, 1984
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a modelF C Lowe, J T Isaacs
Urology|March 1, 1981
Prostate tumor biology and cell kinetics--theoryD S Coffey, J T Isaacs
Endocrinology|February 1, 1984
Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the ratS J Berry, J T Isaacs
Cancer Research|December 1, 1981
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinomaJ T Isaacs, D S Coffey
The Cancer Journal From Scientific American|June 10, 1998
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancerS R Denmeade, J T Isaacs
The Journal of Urology|May 1, 1988
Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapyJ M Henry, J T Isaacs
BJU International|March 11, 2004
The role of prostate-specific antigen in the clinical evaluation of prostatic diseaseS R Denmeade, J T Isaacs
British Journal of Urology|March 1, 1997
Prostate cancer: where are we and where are we going?S R Denmeade, J T Isaacs
The Prostate|September 1, 1996
The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesisI B Joseph, J T Isaacs
Endocrine-Related Cancer|March 27, 2002
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's faultJ T Arnold, J T Isaacs
Pageof 22

Showing results (61-70 of 215) with videos related to

Sort By:
Pageof 22
Cancer Research|February 1, 1984
Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a modelF C Lowe, J T Isaacs
Urology|March 1, 1981
Prostate tumor biology and cell kinetics--theoryD S Coffey, J T Isaacs
Endocrinology|February 1, 1984
Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the ratS J Berry, J T Isaacs
Cancer Research|December 1, 1981
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinomaJ T Isaacs, D S Coffey
The Cancer Journal From Scientific American|June 10, 1998
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancerS R Denmeade, J T Isaacs
The Journal of Urology|May 1, 1988
Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapyJ M Henry, J T Isaacs
BJU International|March 11, 2004
The role of prostate-specific antigen in the clinical evaluation of prostatic diseaseS R Denmeade, J T Isaacs
British Journal of Urology|March 1, 1997
Prostate cancer: where are we and where are we going?S R Denmeade, J T Isaacs
The Prostate|September 1, 1996
The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesisI B Joseph, J T Isaacs
Endocrine-Related Cancer|March 27, 2002
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's faultJ T Arnold, J T Isaacs
Pageof 22